

Tarekegn Geberhiwot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3439075/publications.pdf>

Version: 2024-02-01

21
papers

643
citations

759233

12
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

1008
citing authors

#	ARTICLE	IF	CITATIONS
1	Medium-Term Outcomes in Severely to Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 74, 301-308.	5.8	34
2	Very high bone mineral density in a monogenic form of obesity-associated insulin resistance. <i>Bone</i> , 2021, 143, 115756.	2.9	2
3	REWIND Diabetes for Octogenarians. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2811-e2812.	3.6	0
4	Relative Adipose Tissue Failure in Alstr�m Syndrome Drives Obesity-Induced Insulin Resistance. <i>Diabetes</i> , 2021, 70, 364-376.	0.6	23
5	A case series of cerebral venous thrombosis as the first manifestation of homocystinuria. <i>European Stroke Journal</i> , 2021, 6, 420-427.	5.5	2
6	The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease. <i>Clinica Chimica Acta</i> , 2020, 500, 120-127.	1.1	13
7	Severe neurological crisis in adult patients with Tyrosinemia type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1732-1737.	3.7	5
8	Prospective cardiovascular magnetic resonance imaging in adults with Alstr�m syndrome: silent progression of diffuse interstitial fibrosis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 139.	2.7	3
9	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. <i>Trials</i> , 2019, 20, 314.	1.6	6
10	Challenges in diagnosing and managing adult patients with urea cycle disorders. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 1136-1146.	3.6	41
11	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. <i>Heart</i> , 2019, 105, 1825-1831.	2.9	15
12	Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5� years of treatment. <i>Molecular Genetics and Metabolism</i> , 2018, 123, 479-487.	1.1	23
13	Globotriaosylsphingosine (LysoGb ₃) as a biomarker for cardiac variant (N215S) Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 239-247.	3.6	25
14	Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. <i>Europace</i> , 2018, 20, f153-f161.	1.7	80
15	Treatment with PBI-4050 in patients with Alstr�m syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial. <i>BMC Endocrine Disorders</i> , 2018, 18, 88.	2.2	15
16	Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 52.	2.7	69
17	Advanced non�alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstr�m syndrome. <i>Liver International</i> , 2016, 36, 1704-1712.	3.9	23
18	A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients. <i>Journal of the American Society for Mass Spectrometry</i> , 2016, 27, 719-725.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Duration of Diabetes Predicts Aortic Pulse Wave Velocity and Vascular Events in Alström Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1116-E1124.	3.6	16
20	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases, 2015, 10, 36.	2.7	239
21	PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo. Diabetes, 0, , .	0.6	2